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Summary
Background: Chronic constipation is a common, heterogeneous disorder with multi-
ple symptoms and pathophysiological mechanisms. Patients are often referred to a 
gastroenterology provider after laxatives fail. However, there is limited knowledge of 
the spectrum and management of constipation disorders.
Aim: To discuss the latest understanding of the spectrum of constipation disorders, 
tools for identifying a pathophysiologic- based diagnosis in the specialist setting, 
treatment options and the patient's perspective of constipation.
Methods: Literature searches were conducted using PubMed for constipation diag-
nostic criteria, diagnostic tools and approved treatments. The authors provided in-
sight from their own practices.
Results: Clinical assessment, stool diaries and Rome IV diagnostic criteria can fa-
cilitate diagnosis, evaluate severity and distinguish between IBS with constipation, 
chronic idiopathic constipation and dyssynergic defecation. Novel smartphone ap-
plications can help track constipation symptoms. Rectal examinations, anorectal ma-
nometry and balloon expulsion, assessments of neuromuscular function with colonic 
transit time and colonic manometry can provide mechanistic understanding of un-
derlying pathophysiology. Treatments include lifestyle and diet changes, biofeedback 
therapy and pharmacological agents. Several classes of laxatives, as well as prokinetic 
and prosecretory agents, are available; here we describe their mechanisms of action, 
efficacy and side effects.
Conclusions: Constipation includes multiple overlapping subtypes identifiable using 
detailed history, current diagnostic tools and smartphone applications. Recognition 
of individual subtype(s) could pave the way for optimal, evidence- based treatments 
by a gastroenterology provider.
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1  | INTRODUC TION
Constipation affects 15%- 20% of the global population and carries 
a major health care burden.1,2 The pathophysiology of chronic con-
stipation is complex, exemplified by varying classifications. Patients 
often present with similar, overlapping symptoms.3,4 Therefore, 
differentiation and appropriate classification of constipation types 
guides treatment selection.4,5 Constipation is classified as primary 
or secondary, depending on the underlying cause.3,4 Secondary con-
stipation is associated with organic disease (eg, colonic stricture, 
mass or malignancy), medication use (eg, opioids, anti- cholinergic 
medications) or an underlying condition (eg, metabolic, thyroid or 
diabetic disorders), while primary constipation is a consequence of 
neuromuscular dysfunction of the colon or anorectal sensory- motor 
function.3,6
The complexity of primary constipation— and failure to respond to 
first- line treatments (eg, lifestyle changes and laxatives)— is why pa-
tients are referred to gastrointestinal (GI) specialists.5 Constipation 
disorders are sometimes difficult to manage, and patients are often 
dissatisfied with their treatment.7 Symptoms of constipation can be 
secondary to GI pathology, such as colonic strictures, advanced col-
orectal polyps or neoplasms, necessitating an age- appropriate colon 
cancer screening. Failure to address constipation disorders may re-
sult in symptom progression over time.8
IBS with constipation (IBS- C), functional constipation or chronic 
idiopathic constipation (CIC) and defecatory disorders— especially 
dyssynergic defecation— comprise the most common spectrum of 
primary constipation disorders.9 IBS- C, CIC and dyssynergic def-
ecation have overlapping symptoms.8 Another growing problem is 
opioid- induced constipation (OIC) and, although a secondary cause 
of constipation, significant new knowledge in the pathophysiology 
and treatment of OIC is helpful for GI specialists to consider when 
differentiating from a primary constipation diagnosis.10 Our purpose 
is to provide an up- to- date review on the spectrum of primary con-
stipation disorders, focusing on understanding pathophysiology, 
diagnostic and clinical assessment tools, and pharmacologic and bio-
feedback therapies.
2  | METHODS
For this review, during the period from February 2020 through 
December 2020, literature searches were conducted using PubMed, 
CINAHL and Embase to identify publications reporting on the patho-
physiology, diagnostic criteria, diagnostic tools and approved treat-
ments for constipation. Various combinations of search terms were 
used for IBS- C, CIC or functional constipation and defecation disor-
der. Review of the reference lists from the above searches provided 
additional references, as did additional targeted searches. In sum-
mary, 171 references were selected for inclusion in this review due 
to their relevance to the scope of this manuscript and based on the 
authors' insight, research experience and clinical practices in manag-
ing constipation.
3  | PATHOPHYSIOLOGY
The pathophysiology of constipation is multifactorial and var-
ies between patients. Patients with primary constipation are 
classified as having one of the three overlapping subtypes: def-
ecatory disorders, slow- transit constipation or normal transit 
constipation.3,4,11
Defecatory disorders are often associated with underlying dys-
synergic defecation, characterised by impaired rectal evacuation 
from inadequate rectal propulsion forces, high anal resting pres-
sure and/or paradoxical contraction of the anal sphincter and pel-
vic floor muscles during defecation or incomplete relaxation.3,4,11,12 
Dyssynergic defecation results from uncoordinated contraction of 
the abdominal and pelvic floor muscles.13,14 Difficulty defecating 
may also be compounded by anatomical abnormalities (eg, rectoce-
les, intussusception) or altered rectal sensitivity.3,11
Primary slow colonic transit constipation can be caused by neu-
romuscular dysfunction of the colon wall that is not associated with 
other disorders or underlying systemic diseases.3,11 Colonic motor 
disturbances, or myopathies, are associated with low- amplitude con-
traction resulting in reduced propulsion and colonic stasis leading to 
water reabsorption and stool hardening, accompanied by a reduced 
feeling of the need to defecate.3,11 Colonic neuropathy, associated 
with disorganised or uncoordinated contraction, may include abnor-
mal colonic sensation contributing to abdominal pain and bloating 
and altered neuromuscular signalling in and/or to the colonic wall.3,11 
The colons of patients with chronic constipation have shown a re-
duced number of intrinsic nerves and interstitial cells of Cajal and a 
decreased response to cholinergic stimulation.3,11 Evidence suggests 
that methane gas accumulation in the GI tract, or intestinal metha-
nogenic overgrowth, is associated with reduced colonic transit and 
slow transit constipation15; however, a separate study presented 
conflicting data where breath methane excretion was not associated 
with slow colonic transit.16 The prevalence of methane- producing 
flora— and baseline methane levels— is significantly higher in patients 
with delayed colonic transit than with normal transit, and negatively 
correlate with colonic transit.17
The pathophysiology of CIC and IBS- C is multifactorial, involv-
ing visceral hypersensitivity, neuropathy along the afferent gut- 
brain axis, altered bile acid metabolism, neurohormonal regulation, 
immune dysfunction, gut microbiota dysbiosis, alterations in the 
epithelial barrier, secretory properties and brain and gut dysfunc-
tion.18- 20 These diagnoses of primary constipation are not exclusive, 
as patients may have co- existing defecation disorder, slow transit, 
CIC or IBS- C.3,11 Consequently, with an unrecognised or untreated 
dyssynergia (or an overlapping rectal evacuation disorder), there is a 
potential for secondary delays in colonic transit.
Approximately, 40% of opioid- using patients report OIC regard-
less of opioid potency.21 Without treatment, opioid- related bowel 
disorders, mainly constipation, significantly decrease the quality of 
life (QoL) and daily activities.22 The robust interaction of opioids 
with µ- receptors in the enteric nervous system, rather than ef-
fects of opioids in the central nervous system, results in decreased 
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GI transit, stimulation of non- propulsive activity, increased anal 
tone, decreased intestinal secretion, increased fluid adsorption 
and decreased rectal sensitivity. The net effort of these mecha-
nisms induced by opioids is to cause constipation and bowel- based 
dysfunctions.10
4  | DIAGNOSTIC TOOL S
The term ‘constipation’ is non- specific, referring to a constellation 
of patient- reported symptoms describing a bowel function dis-
turbance.23,24 However, clinicians should be able to characterise 
constipation's varied features.23,24 Visual images of stool form, spe-
cifically the Bristol Stool Form Scale (BSFS; Figure 1), and bowel 
diaries are reliable methods to characterise bowel habits. A self- 
administered mobile phone app, Constipation Stool Diary, provides 
information about constipation symptoms that a patient can keep 
prospectively for 1- 2 weeks, reducing recall bias and improving 
treatment response monitoring (Figure 2).25
Symptoms of chronic constipation alone do not accurately pre-
dict the underlying pathophysiology or response to treatment.26 
Providers should be familiar with ‘alarm features’ that suggest a more 
serious underlying health issue (eg, occult colon cancer), so appropri-
ate testing (eg, colonoscopy) can be arranged. Alarm features include 
bloody stools, anaemia or iron deficiency, unintentional weight loss 
and family history of colorectal cancer.5,27
4.1 | Diagnostic criteria
Chronic constipation can be diagnosed via Rome IV criteria, which 
incorporate patient- reported symptoms, stool consistency, physical 
examination and motility study findings (Table 1).28 In addition to 
stool frequency, stool shape and consistency are also key compo-
nents of the diagnostic criteria, and the BSFS is recommended for 
characterising stool appearance (Figure 1).3,28,29 The BSFS describes 
seven stool consistency categories correlating with colonic transit 
time.29 Longer transit times are associated with lower BSFS scores. 
Sensations of incomplete emptying, straining, use of digital manoeu-
vres for evacuation of stool and abdominal bloating/distension can 
indicate underlying constipation.4
Before diagnosing primary constipation, gastroenterology pro-
viders should first rule out secondary causes of constipation. A 
thorough medication history can identify exacerbating medications, 
opioids and anti- cholinergic medications. Secondary constipation 
may also be a result of diabetes mellitus, chronic renal disease, dehy-
dration, Parkinson's disease, Ehlers- Danlos syndrome or other con-
nective tissue disorders.3,30,31
F I G U R E  1   Bristol Stool Form Scale. Copyright 2000 © by Rome 
Foundation. All Rights Reserved
Type 1 Separate hard lumps, like nuts
Sausage-shaped but lumpy
Like a sausage but with
cracks on the surface
Like a sausage or snake,
smooth and soft
Soft blobs with clear-cut
edges
Fluffy pieces with ragged
edges, a mushy stool







F I G U R E  2   Parameters in Constipation 
Stool Diary in constipated and healthy 
subjects. This figure has been reproduced 
from Yan et al Gastroenterology 2020 with 
permission from Elsevier.25 BM, bowel 
























CSBM Time/BM Gas episodes Bloating episodes
***P<0.001 vs healthy subject.
0
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Primary chronic constipation can be further investigated by 
multiple tests. Defecatory disorders are evaluated by digital rectal 
examination, rectal balloon expulsion, anorectal manometry and 
defecography.5,6,27
4.2 | Physical examination
Comprehensive abdominal and thorough digital rectal examinations 
are useful in evaluating chronic constipation.11,32 Close inspection 
of the perianal region can reveal excoriations, haemorrhoids, fis-
sures or masses. A lubricated finger in the anal canal can assess anal 
sphincter tone. Placing one hand on the lower abdomen while a fin-
ger is inserted into the anal canal assesses rectoanal incoordination 
or dyssynergic defecation.3,11,29,33,34 If constipation is fibre- and lax-
ative refractory, then physiological testing should be considered.29 
Often, patients will have already attempted self- treatment with fibre 
and laxatives before seeing a health care provider.26
4.3 | Functional tests
High- resolution anorectal manometry and balloon expulsion 
testing are simple, inexpensive and the first anorectal physi-
ological tests recommended for patients with laxative- refractory 
CIC or suspected dyssynergic defecation, with high sensitiv-
ity for detecting dyssynergia and rectal hypersensitivity or 
hyposensitivity.4,11,28,32
TA B L E  1   Rome IV diagnostic criteria for IBS with constipation,43 functional constipation43 and functional defecation disorders28
IBS with Constipation (IBS- C)
Criteria fulfilled for the last 3 mo with symptom onset ≥6 mo prior to diagnosis
Recurrent abdominal pain, on average, ≥1 d per week in the last 3 mo, associated with two or more of the following criteria:
• Related to defecation
• Associated with a change in frequency of stool
•  Associated with a change in form (appearance) of stoolDiagnostic criteria for IBS subtypes
Predominant bowel habits are based on stool form on days with at least one abnormal bowel movementa 
IBS with predominant constipation: More than one fourth (25%) of bowel movements with BSFS types 1 or 2 and less than one fourth (25%) of 
bowel movements with BSFS types 6 or 7
Alternative for epidemiology or clinical practice: Patient reports that abnormal bowel movements are usually constipation (like type 1 or 2 in the 
picture of BSFS).
Functional constipation (Chronic idiopathic constipation [CIC])
Criteria fulfilled for the last 3 mo with symptom onset at least 6 mo prior to diagnosis
1. Must include two or more of the following:
• Straining during more than one fourth (25%) of defecations
• Lumpy or hard stools (BSFS 1- 2) more than one fourth (25%) of defecations
• Sensation of incomplete evacuation more than one fourth (25%) of defecations
• Sensation of anorectal obstruction/blockage more than one fourth (25%) of defecations
• Manual manoeuvres to facilitate more than one fourth (25%) of defecations (eg, digital evacuation, support of the pelvic floor)
• Fewer than three spontaneous bowel movements per week
2. Loose stools are rarely present without the use of laxatives
3. Insufficient criteria for IBS- C
Functional defecation disorders
Criteria fulfilled for the last 3 mo with symptom onset at least 6 mo prior to diagnosis
1. The patient must satisfy diagnostic criteria for functional constipation and/or IBS- C
2. During repeated attempts to defecate, there must be features of impaired evacuation, as demonstrated by two of the following three tests:
• Abnormal balloon expulsion test
• Abnormal anorectal evacuation pattern with manometry or anal surface electromyography
• Impaired rectal evacuation by imaging
3. Subcategories F3a and F3b apply to patients who satisfy criteria for a functional defecation disorderF3a. Diagnostic criteria for inadequate 
defecatory propulsion
Inadequate propulsive forces as measured with manometry with or without inappropriate contraction of the anal sphincter and/or pelvic floor 
musclesb 
F3b. Diagnostic criteria for dyssynergic defecation
Inappropriate contraction of the pelvic floor as measured with anal surface electromyography or manometry with adequate propulsive forces 
during attempted defecationb 
Abbreviations: BSFS, Bristol Stool Form Scale; CIC, chronic idiopathic constipation; IBS- C, IBS with constipation.
aIBS subtypes related to bowel habit abnormalities can only be confidently established when the patient is evaluated off medications used to treat 
bowel habit abnormalities.
bThese criteria are defined by age- and sex- appropriate normal values for the technique.
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4.3.1 | Balloon expulsion test
The balloon expulsion test is an office- based test assessing a pa-
tient's ability, based on time taken, to expel a water- or air- filled 
balloon inserted into the rectum.28,32,35,36 Standardisation is lacking 
and methodology differs between GI motility laboratories,32,35 but 
an expulsion time longer than 1- 2 minutes is generally considered 
abnormal.28 An uncontrolled study of patients with constipation and 
defecation disorders illustrated that the balloon expulsion test may 
identify patients with dyssynergic defecation.37 Some GI motility 
laboratories use the balloon expulsion test to screen for dyssynergic 
defecation. However, a normal test does not always exclude defeca-
tory dysfunction, and correlation with other anorectal physiological 
testing and defecography is lacking.5,11,29,38 Patient demographics 
can also affect test results: males typically have a shorter expulsion 
time, and expulsion time lengthens with increasing age.35 Therefore, 
corresponding tests of anorectal physiological function should be 
obtained.28,29
4.3.2 | Anorectal manometry
Anorectal manometry assesses anorectal pressure changes during 
rest and simulated defecation of an intrarectal balloon, sphincter 
tone and rectoanal reflexes (which evaluate intrinsic and extrinsic 
innervation, and rectal compliance and sensitivity).5,28,29,32 Although 
more expensive, high- resolution anorectal manometry using a six- 
sensor, solid- state probe permits easier calibration and shorter pro-
cedure time compared to conventional water- perfused anorectal 
manometry.39 Anorectal manometry is useful in diagnosing dyssyn-
ergic or disordered defecation and other neuromuscular and sensory 
problems, and identifying patients who may benefit from biofeed-
back therapy.5,32,40,41
While effective and widely used, anorectal manometry has lim-
itations. Substantial variations in clinical practice in methodologies 
used for the balloon expulsion test and anorectal manometry32,36 
demand prompt efforts to standardise testing protocols.36,40 A 
standardised protocol of high- resolution anorectal manometry 
can characterise dyssynergic defecation subtype of rectoanal in-
coordination and guide therapists providing corrective biofeedback 
therapy treatment.36 Furthermore, patient cooperation is key,11 
the procedure may be embarrassing11 and test performance may 
not accurately replicate the actual act of defecation.28 If the bal-
loon expulsion or anorectal manometry test fails to diagnose or 
exclude a strongly suspected defecatory disorder, defecography is 
recommended.11,28
4.3.3 | Defecography
Defecography examines both the function and structure of the 
anorectum and the pelvic floor during voluntary defecation.28,29 
Defecography is performed in specialist centres, using X- ray 
(barium) or magnetic resonance imaging.28,32,35 X- ray defecography 
assesses rectal wall structure and pelvic floor motion while seated. 
Magnetic resonance imaging defecography evaluates all pelvic com-
partments in the semi- recumbent position, which may not replicate 
the everyday practice of defecation.35 These tests can determine 
if chronic constipation is associated with incomplete anal opening, 
impaired puborectalis relaxation or contraction, abnormal perineal 
descent and anatomical abnormalities (eg, rectocele, prolapse or 
intussusception).5,29
4.4 | Assessing colonic transit time
Slow colonic transit time can contribute to constipation and is as-
sessed by measuring the time taken for content to move through 
the GI system.32 Colonic transit assessment is recommended in 
the evaluation of laxative- refractory constipation.11,32 Specialist 
centres evaluate colonic transit time either by radiopaque mark-
ers, wireless motility capsules or by scintigraphy.5,11,27,28,42 Colonic 
transit tests should be performed while the patient is not taking a 
laxative.43
4.4.1 | Radiopaque marker test
Radiopaque marker testing is widely accessible, non- invasive, inex-
pensive and the most common option for assessing colonic transit 
time.5,28,29,42 In a radiopaque marker test, the patient ingests a dis-
solvable capsule containing 20- 50 plastic markers.42 The radiopaque 
markers are visible on X- ray. Transit time is calculated from abdomi-
nal radiographic images captured at set time points in the days fol-
lowing capsule ingestion.42 Variations in the radiopaque marker test 
are used in gastroenterology clinical practice.42 The most commonly 
applied method involves administering a capsule containing 20- 24 
markers on day 1, followed by abdominal radiograph imaging after 
5 days29,42; retention of >20% of ingested markers indicates slow 
colonic transit.29
4.4.2 | Wireless motility capsule test
Wireless motility capsules enable radiation- free, continuous mon-
itoring of the intraluminal pH, pressure and temperature while 
passing through the GI tract.29,42,44 Signals from the capsule are 
transmitted to a receiver the patient wears. After capsule inges-
tion following an overnight fast, patients record events (eg, meals, 
bowel movements, symptoms) over 3- 5 days by pressing a re-
ceiver button and maintain a diary.44 Results have demonstrated 
good correlation with radiographic tests.28,44,45 Wireless motility 
capsules provide a comprehensive picture with other regional GI 
transit times (gastric emptying time, small- bowel transit time) and 
whole- gut transit time.44,46 The capsule measures colonic transit 
time by detecting pH changes while moving through the gut.29,44 
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Demographics and study protocols can influence test findings.47 
Transit times are shorter among males and can vary with the men-
strual cycle.47
4.4.3 | Scintigraphy
Scintigraphy uses repeated imaging of ingested radioisotopes over 
consecutive days to calculate overall and regional colonic transit 
times.29,42 A range of γ- emitting isotopes, administered in varying 
vehicles, may be used.42 Scintigraphy testing is conducted at a few 
specialised centres, due to the need for specialist equipment and use 
of short- lived radioactive isotopes.42
4.4.4 | Colonic manometry
In cases of severe slow- transit constipation and suspected colonic 
inertia, ambulatory 24- hour colonic manometry following a stand-
ardised protocol can help distinguish between underlying colonic 
myopathy and neuropathy, facilitating appropriate management.48 
Like scintigraphy, colonic manometry is limited to a few, specialised 
centres.
5  | DIAGNOSTIC FE ATURES
5.1 | Chronic idiopathic constipation
CIC is estimated to affect 14% of the global population.1 Patients 
with CIC may report lumpy or hard stools (BSFS type 1- 2) and in-
frequent bowel movements (<3 per week). Straining and abdominal 
bloating may be present. Pain may also be present, but it would not 
predominant.43 Evaluation of patient's history may find sensation of 
incomplete evacuation or anorectal obstruction, and patients may 
report using manual manoeuvres to facilitate defecations. Discussion 
with the patient may reveal limited physical activity, QoL complaints, 
attempted use of laxatives and infrequent loose stools without the 
use of laxatives. A rectal examination and routine blood tests would 
likely be normal and there may be no immediate indication of alarm 
features or physical abnormalities. More invasive diagnostic tests 
may be necessary if symptoms are not relieved with prescription 
therapy. In patients with laxative- refractory constipation, colonic 
transit assessment may be informative.
5.2 | IBS with constipation
Approximately 5.2% of the North American population is estimated 
to experience IBS- C.49 In order to diagnose IBS- C based on the Rome 
IV criteria, a review of the patient's medical history would reveal re-
current abdominal pain associated with defecation, reductions in 
stool frequency and/or a change in stool consistency.43 Assessment 
of a patient's stools via BSFS would reveal more than 25% of bowel 
movements with BSFS types 1 or 2 and less than 25% of bowel 
movements with BSFS types 6 or 7.43 Predominant abdominal pain 
would likely distinguish IBS- C from CIC. Laxatives may help improve 
bowel movement frequency, but they may not improve abdominal 
symptoms (eg, bloating and pain). Digital rectal examination, anorec-
tal manometry and balloon expulsion would determine the coexist-
ence of disordered or dyssynergic defecation.
5.3 | Defecatory disorder
As with CIC, patients may have infrequent and hard bowel move-
ments, bowel movements associated with excessive straining, or a 
feeling of incomplete evacuation, and may use digital evacuation ma-
noeuvres. Laxatives may not improve feelings of incomplete evacua-
tion, straining and hard stools. A detailed history may reveal natural 
birth experience in women. Digital rectal examination, rectal balloon 
expulsion, anorectal manometry and defecography would help diag-
nose defecatory disorders.27 In a digital rectal examination, a patient 
may have a normal sphincter tone at rest, but when asked to push 
and bear down may exhibit paradoxical contraction of anal sphincter 
with no perineal descent, suggesting dyssynergia.34 The patient may 
be unable to pass the balloon expulsion test,37 and results from ano-
rectal manometry would show consistency with dyssynergic defeca-
tion. Biofeedback therapy using visual manometry- based feedback 
would likely be helpful.
6  | TRE ATMENT
The initial management approach to IBS- C and CIC tends to be simi-
lar, but therapy response varies between the two conditions.9 For 
example, stimulant laxatives and polyethylene glycol (PEG) can be 
effective for CIC but not for IBS- C.9 The symptomatology of def-
ecatory disorders, such as dyssynergic defecation, can overlap with 
IBS- C and CIC; however, symptoms of excessive straining, feeling of 
incomplete evacuation and use of digital manoeuvres to defecate 
are more prevalent. Defecatory disorders are less likely to respond 
to laxative therapy and more likely to require biofeedback therapy.2
6.1 | Lifestyle and dietary modifications
Initial therapy for chronic constipation includes lifestyle and di-
etary modifications (eg, increasing fluid and fibre intake) and physi-
cal activity.28,29,32 Little evidence suggests that increasing fluid 
intake alone improves stool consistency among adequately hy-
drated patients.28,29,50 Instead, increased fluid intake is most ben-
eficial when combined with additional fibre in patients with mild 
constipation.28,32,50
Increasing fibre intake, which should be done gradually to pre-
vent abdominal distension,11,28,32 may improve constipation by 
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stimulating the gut mucosa to secrete water and mucus and im-
prove stool consistency by increasing its water- holding capacity.29 
However, not all constipation patients benefit from additional di-
etary fibre.50 Insoluble fibre (eg, fibre in wheat bran and whole grains) 
may worsen symptoms of abdominal pain, distension and flatulence 
in some patients.28,29,32 Fruit fibre (eg, prunes51) or mixed soluble 
fibre52 has demonstrated a short- term efficacy in the management 
of chronic constipation, somewhat better than psyllium. In a recent 
randomised controlled trial of natural treatments for CIC in 79 pa-
tients, kiwifruit, psyllium and prunes were found to be effective.53
Physical activity has been associated with reduced GI transit 
times.50 Although exercise alone does not appear to improve con-




Laxatives are an inexpensive, widely available and often over- the- 
counter (OTC) treatment option for chronic constipation refractory 
to lifestyle and dietary modifications.11,32 Laxatives can improve 
stool consistency, increase stool frequency and reduce defecation 
straining.54
Osmotic laxatives
Osmotic laxatives, such as PEG, lactulose, sorbitol, glycerol and 
magnesium salts, contain non- absorbable ions or molecules.28,32 
These compounds create an osmotic gradient that promotes water 
and electrolyte secretion into the intestinal lumen, increasing faecal 
volume and improving peristalsis.29,32 Most studies have focused on 
PEG, which has demonstrated superiority over placebo and lactulose 
in improving symptoms of chronic constipation.29,50 PEG treatment 
shows greater resolution of constipation symptoms,55,56 improved 
stool consistency and frequency,55- 57 shorter GI transit time,57 less 
straining,55- 57 and less severe abdominal bloating and pain compared 
with placebo.55 PEG is also better than lactulose in improving stool 
consistency and frequency, reducing abdominal pain , and need for 
additional  constipation- related treatment.58,59 Improvements in 
bowel movements, stool consistency and straining with PEG treat-
ment have also been observed in patients with IBS- C, though ab-
dominal pain is largely unaffected.50,60,61 Osmotic laxatives are 
generally well tolerated.32,55,60 The most common adverse events 
(AEs) are abdominal pain and distension, diarrhoea, nausea, flatu-
lence and vomiting.28,56,57,61 Magnesium compounds should be used 
with caution in patients with renal impairment.
Stimulant laxatives
Stimulant laxatives are recommended after patients have failed to 
respond to osmotic laxatives.11,29 Diphenylmethane derivatives (eg, 
bisacodyl, sodium picosulfate) and anthraquinones (ie, sennosides, 
cascara) are inactive, non- absorbable glycosides that stimulate fluid, 
electrolyte secretion and peristalsis upon activation by glycosidases 
in the colon.28,29,32,50 Stimulant laxatives are commonly used for pa-
tients with CIC and IBS- C, though large controlled studies are lack-
ing.29,50 Both bisacodyl and sodium picosulfate can improve stool 
consistency and frequency, straining and QoL compared with pla-
cebo in CIC patients in randomised controlled trials.62- 64 The most 
common AEs with stimulant laxatives include diarrhoea, abdominal 
pain, nausea, vomiting and headache.28,32,62
6.2.2 | Prokinetic and prosecretory agents
Table 2 and Figure 3 detail the mechanisms of action by which the 
following types of prokinetic and prosecretory agents improve con-
stipation symptoms.
Guanylate cyclase- C receptor agonists
Guanylate cyclase- C (GC- C) receptors are transmembrane proteins 
expressed by intestinal epithelial cells and help maintain bowel 
function by regulating fluid and electrolyte balance in the gut.65 
Activated GC- C receptors facilitate the production of an ion gra-
dient between the intestinal membrane and intestinal lumen that 
promotes net water movement into the gut27,66 by simultaneous 
activation of cystic fibrosis transmembrane conductance regulator 
channels and inhibition of sodium/hydrogen exchanger isoform 3 
channels.65,67 Furthermore, GC- C receptor activation helps maintain 
the intestinal mucosal barrier, prevent inflammation and attenuate 
visceral pain sensations.67
The GC- C receptor is activated by the hormones uroguanylin 
and guanylin and by heat- stable enterotoxins produced by diar-
rhoeagenic bacteria.67 Uroguanylin and guanylin both have two 
disulphide bonds resulting in a flexible structure with active forms 
stabilised at a specific pH.67 Uroguanylin binds more readily to 
GC- C receptors in slightly acidic conditions of the duodenum and 
jejunum (pH 5- 6), while guanylin binds to GC- C receptors in more 
neutral to slightly basic conditions of the ileum and the colon (pH 
7- 8).65,67 In contrast to uroguanylin and guanylin, heat- stable en-
terotoxins produced by diarrhoeagenic bacteria are stabilised by 
a third disulphide bond, producing a more stable and higher affin-
ity structure.67 Heat- stable enterotoxins lack pH- sensitive amino 
acids, allowing for GC- C binding throughout the GI tract without 
being affected by gut pH.67
GC- C also helps regulate pain experienced in patients with 
chronic constipation, especially those with IBS- C.26,68 Activation 
of GC- C inhibits nociception in the gut, reducing pain.68 GC- C is a 
target for pharmacological therapy because activating this receptor 
can increase fluid secretion and accelerate colonic transit time, re-
storing normal bowel function.65,68 Furthermore, a recent report has 
demonstrated reduced uroguanylin levels in IBS- C and CIC patients 
when compared to healthy control subjects during fasting and after 
meals.69
Linaclotide, a synthetic analogue of exogenous diarrhoeagenic 
bacterial heat- stable enterotoxins, and plecanatide, a synthetic 
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uroguanylin analogue, are GC- C agonists approved by the US Food 
and Drug Administration for the treatment of CIC and IBS- C.66 In 
clinical studies, linaclotide and plecanatide significantly improved 
stool consistency and frequency, and reduced straining, in patients 
with CIC or IBS- C.54,70- 81 Patients also report improvements in ab-
dominal discomfort, constipation severity and QoL,54,70,73- 79,82,83 
with sustained efficacy over 24 and 52 weeks of treatment.82 
Linaclotide and plecanatide also reduce abdominal pain, bloating 
and cramping in patients with IBS- C.71,72,78,80- 83 Improvements in 
IBS- C symptoms were maintained over 12 and 26 weeks of treat-
ment.83 Japanese patients with IBS- C may require a higher dose 
of linaclotide, possibly due to differences in GC- C polymorphisms, 
bacterial proteases that metabolise linaclotide and/or diet compared 
with Western patients.82
Linaclotide and plecanatide are well tolerated. Diarrhoea is the 
most frequent AE, but is generally mild or moderate in severity 
and occurs during the first 4 weeks of treatment.54,70- 82,84,85 No 
head- to- head trials have been conducted, and so direct com-
parisons cannot be made between the products; however, rates 
of diarrhoea reported in clinical trials of linaclotide were higher 
relative to those in plecanatide trials.71,73,76- 79 While this may be 
related to the similarity of plecanatide to endogenous uroguanylin 
and linaclotide to heat- stable enterotoxins,67 there were also dif-
ferences between the plecanatide and linaclotide study designs 
that should be considered. Linaclotide, but not plecanatide, trials 
permitted dose interruptions (ie, patients could halt treatment to 
resolve a diarrhoea AE), which may have contributed to artificially 
lower rates of discontinuation due to diarrhoea. Additionally, while 
in both trials any verbatim report of ‘diarrhoea’ was recorded as an 
AE, in plecanatide studies, an extra level of scrutiny was added. 
When a patient reported increased stool frequency or looser 
stools, an assessment of ‘bothersome’ was made to determine if 
TA B L E  2   Mechanism of action of pharmacological treatments for chronic constipation
Drug
Recommended 
dosea  Mechanism of action Efficacy Adverse events
Polyethylene 
glycol
Non- prescription Osmotic 
laxative
• Creates an osmotic 
gradient that promotes 
water and electrolyte 
secretion into the 
intestinal lumen
• Improves stool consistency and 
frequency55,57
• Reduces straining55,57




Bisacodyl Non- prescription Stimulant 
laxative
• Stimulates water and 
electrolyte secretion, 
and peristalsis
• Improves stool consistency 
and frequency, straining and 
QoL62- 64
• Diarrhoea, abdominal 






Plecanatide CIC or IBS- C: 
3 mg q.d.
GC- C agonist • Increases intracellular 
cyclic guanosine 
monophosphate, creating 
an ion gradient that 
promotes fluid secretion
• Inhibits colon 
nociception
• Improves stool consistency and 
frequency, reduces straining 
and abdominal discomfort, 
improves QoL54,70- 82
• Reduces abdominal 
pain, bloating and 
cramping71- 73,78,80- 83
• Diarrhoea54,70- 82,84,85
Linaclotide CIC: 145 mcg 
q.d. and 72 
mcg q.d.
IBS- C: 290 mcg 
q.d.
Prucalopride CIC: 2 mg q.d.b  5- HT4 
agonist
• Accelerates GI motility • Improves constipation 
symptoms, including stool 
consistency and frequency, 
straining QoL96- 98,167




Tegaserod IBS- C: 6 mg 
b.i.d.c 







• Creates an ion gradient 
that promotes water and 
sodium secretion into the 
intestinal lumen
• Improves constipation 
symptoms, including stool 
consistency and frequency, and 
abdominal pain103
• Diarrhoea103
Lubiprostone CIC: 24 mcg 
b.i.d.






• Creates an ion gradient 
that promotes water and 
sodium secretion into the 
intestinal lumen
• Improves stool consistency and 
frequency, reduces straining, 
bloating and pain54,113- 122
• Nausea, 
diarrhoea54,113- 118,121,122
Abbreviations: b.i.d., twice daily; CIC, chronic idiopathic constipation GC- C, guanylate cyclase- C; GI, gastrointestinal; IBS- C, IBS with constipation; 
q.d., once daily; QoL, quality of life.
aPrescription doses are based on US Food and Drug Administration approval. Not all prescription therapies are approved outside the United States; 
treatment options should take into account therapy availability.
bIndicated for patients with CIC (2 mg q.d.) or for patients with severe renal impairment (1 mg q.d.)
cIndicated for women aged <65 y.
dIndicated for women aged ≥18 y.
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this report should be recorded as diarrhoea AE or a desired effect 
of the drug.86
Serotonin agonists
Serotonin (5- hydroxytryptamine) is a gut neurotransmitter that 
promotes motility via several serotonin receptor subtypes in the GI 
tract.28,87 Serotonin controls gut smooth- muscle contractions and 
relaxations.88 Patients with IBS- C may have dysfunctional serotonin 
neurotransmission in the gut.87,88 In a healthy individual, serotonin 
plasma levels increase after food consumption; however, in IBS- C 
patients, there may be limited or no response.88,89 Alternatives in 
serotonin transporter gene polymorphism in IBS and in constipation 
have been reported.90 This dysfunctional serotonin signalling may 
be associated with altered colonic transit.89 In patients with slow- 
transit constipation, levels of serotonin- immunoreactive cells are 
significantly lower, so cell secretory indexes are decreased in these 
patients' colons.91
Several agents have been developed that target the sero-
tonin receptor 5- HT4 to promote peristalsis and secretion.
92,93 
Prucalopride and velusetrag (currently under clinical investi-
gation) are selective, high- affinity 5- HT4 agonists that increase 
GI motility and reduce colonic transit times.92- 94 Earlier 5- HT4 
agonists, including cisapride and tegaserod, had poor selectiv-
ity and low affinity for the 5- HT4 receptor, were associated with 
serious cardiovascular AEs, and, consequently, market with-
drawal.92,93 After data re- examination, tegaserod has been re- 
approved for the treatment of IBS- C in women <65 years old, 
with a contraindication in patients with a history of cardiovascu-
lar issues.95 In randomised, placebo- controlled phase 3 studies, 
prucalopride was superior to placebo in improving symptoms, 
stool consistency and frequency, and reduced straining on defe-
cation in patients with CIC.96- 98 Improvements in disease sever-
ity and QoL,96- 98 with patient satisfaction of bowel pattern, were 
noted and treatment efficacy was maintained for ≥18 months.99 
Prucalopride's efficacy for improving symptoms of constipation 
was confirmed in several integrated analyses and meta- analyses; 
however, no evidence has been published demonstrating efficacy 
for pain so prucalopride is not approved for the treatment of 
IBS- C.54,100- 102
Prucalopride- associated AEs include GI complaints (nau-
sea, abdominal pain, diarrhoea), flatulence and headache.54,96- 
98,100- 102 However, prucalopride is well tolerated, with AEs 
generally being mild, transient and resolving after the first day of 
treatment.96,99,102
F I G U R E  3   Mechanism of action of agents used for the treatment of constipation. This figure has been modified from Simrén et al Nature 
Reviews Gastroenterology & Hepatology 2018 with permission from Springer Nature Customer Service GmBH: Wiley.171 ACh, acetylcholine; 
CFTR, cystic fibrosis transmembrane conductance regulator; ClC- 2, type- 2 chloride channel; GC- C, guanylate cyclase- C; IBAT, ileal bile acid 
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Sodium/hydrogen exchanger isoform 3 inhibitors
Inhibition of GI sodium/hydrogen exchanger isoform 3 expressed on 
the apical surface of the small intestine and colon reduces absorp-
tion of sodium from the small intestines and colon.103 This results in 
water secretion into the intestinal lumen, increases intestinal transit 
time and softens stool consistency. Tenapanor, a sodium/hydrogen 
exchanger isoform 3 inhibitor, is approved by the US Food and Drug 
Administration for IBS- C treatment.103
In a phase 3 study, patients treated with tenapanor demon-
strated improvements in stool frequency and reductions in abdomi-
nal pain.103 Diarrhoea was the most common adverse reaction, with 
treatment- related diarrhoea reported in 13.3% of tenapanor- treated 
patients.103
Bile acid modulation
Dysfunction in the enterohepatic circulation of bile acids can cause 
constipation.87 Bile acids that are not absorbed in the terminal ileum 
can stimulate water and electrolyte secretion in the colon and di-
rectly contribute to colonic motility independent of secretory ef-
fects.104 A subset of patients with IBS- C may exhibit lower bile 
acid levels in their stools than in those of healthy controls and of 
patients with diarrhoea- predominant IBS,87 which may be attributed 
to altered bile acid synthesis in these patients.105 Modulation of the 
bile acid cycle may help treat chronic constipation and involves bile 
acid supplementation or inhibition of the ileal bile acid transporter. 
Sodium chenodeoxycholate is a bile salt that can accelerate colonic 
transit times and improve stool consistency and frequency in pa-
tients with chronic constipation, including IBS- C.106,107
Elobixibat (approved in Japan) is a minimally absorbed, highly 
selective ileal bile acid transporter inhibitor. By inhibiting the ac-
tive reabsorption of bile acids in the ileum, elobixibat increases 
bile acid concentrations in the colon, promoting fluid secretion 
and motility.108 Elobixibat increases stool frequency and improves 
constipation- associated symptoms, including stool consistency, con-
stipation severity, straining and abdominal bloating in CIC and IBS- C 
patients.108- 110
Both sodium chenodeoxycholate and elobixibat are generally 
well tolerated. AEs are typically mild and GI- related, most commonly 
abdominal pain and diarrhoea.107- 110 Given elobixibat demonstrates 
minimal systemic absorption,110 increased bile acids may stimulate 
propagated contractions in the colon, resulting in abdominal pain 
and cramping.111
Chloride channel activators
Chloride channels located on intestinal epithelial cells regulate in-
testinal motility and fluid secretion.92 Activation of type- 2 chloride 
channels triggers the release of chloride ions into the intestinal 
lumen.92 The resulting ion gradient promotes sodium and water re-
lease into the lumen, increasing stool volume and GI motility while 
reducing colonic transit time.92
Lubiprostone, a bicyclic fatty acid and a prostaglandin E1 an-
alogue, is a locally acting selective type- 2 chloride channel ago-
nist.28,32,92,112 Lubiprostone has demonstrated efficacy in improving 
stool consistency and frequency and in reducing straining, bloating 
and constipation severity in patients with CIC or IBS- C.7,54,113- 121 
Lubiprostone treatment also reduces abdominal pain/discomfort and 
improves QoL for patients with IBS- C.115,117,118,120,121 Improvements 
are maintained with long- term treatment.113,117,120
GI- related AEs are most common with lubiprostone treatment 
(predominantly nausea and diarrhoea), though headaches were also 
reported.54,113- 118,121,122 AEs tend to be mild or moderate in intensity 
and short lived.113- 115,117,118,121 A recent study using pooled trial data 
demonstrated that lubiprostone did not affect electrolyte homeo-
stasis in the short or long term.123
Opioid receptor antagonists
The mechanism by which opioid medications induce constipation is 
complex, involving peripheral and central effects. Peripheral activa-
tion of µ- opioid receptors in the stomach and intestines inhibits both 
excitatory and inhibitory neural pathways, diminishing peristalsis 
and colonic transit time and delaying gastric emptying.124 Evidence 
for a central mechanism is supported by a study in rats where intra- 
cerebroventricular morphine administration inhibited GI propul-
sion.124 In patients with laxative- refractory OIC, opioid receptor 
antagonists with peripheral or peripheral and central action may be 
used. Although OIC is a secondary cause of constipation, many of 
which may be relieved by treating the primary problem, it is the only 
secondary cause of constipation with specific therapies and is po-
tentially reversible with treatment (unlike other secondary causes). 
Several therapies for OIC are approved by the US Food and Drug 
Administration.125 The American Gastroenterological Association's 
guidelines on the management of OIC distinguishes between tradi-
tional laxatives and peripherally acting µ- opioid receptor antagonists 
and other prescription therapies for this condition. These guidelines 
recommend traditional laxatives (including PEG) as first- line treat-
ment for OIC, while peripherally acting µ- opioid receptor antago-
nists and other prescription therapies are recommended for patients 
who fail traditional laxatives.126 Meta- analysis of the safety and ef-
ficacy of current OIC treatments has recently been published.127
6.3 | Biofeedback therapy for 
dyssynergic defecation
Biofeedback therapy is a robust treatment for dyssynergic defeca-
tion diagnosed by symptoms and anorectal motility testing, receiv-
ing a Grade A recommendation by the American and European 
Societies of Neurogastroenterology and Motility.128 Multiple ran-
domised controlled studies have proven that four to six sessions of 
electromyography or manometry- based biofeedback therapy carries 
a 70%- 80% efficacy rate for dyssynergic defecation compared to 
standard treatment,129 diltiazem130 or laxatives.131 Furthermore, bi-
ofeedback therapy, incorporating rectoanal coordination, simulated 
defecation and sensory conditioning, is durable, and separate stud-
ies have shown a sustained response for 12 and 44 months.132,133 
Severe constipation, digital facilitation of defecation, delayed 
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colonic transit, impaired rectal sensation and increased anorectal 
angle during squeeze are predictors of poor response to biofeed-
back therapy.134- 136 Standard office- based biofeedback therapy suf-
fers from limitations: the need for skilled staff, multiple visits and 
limited availability at expert centres. Home biofeedback therapy is 
appealing for dyssynergic defecation and has similar efficacy in im-
provement of bowel symptoms and balloon expulsion compared to 
office- based therapy.137 Furthermore, home biofeedback therapy is 
more cost- effective and shows promise for the future.138
6.4 | Clinical approach to managing patients with 
constipation
Management algorithms are available to help guide treatment deci-
sions (Figure 4) and a recent meta- analysis evaluating the efficacy of 
constipation treatments has been published.139 First- line treatment 
for chronic constipation patients failing lifestyle modifications in-
clude fibre supplements or osmotic laxatives (such as PEG) on a reg-
ular basis, or stimulant laxatives intermittently,50 which are available 
to patients as OTC products.11,28,29,32,140 Indeed, many patients with 
chronic constipation will use some OTC laxative before consulting a 
health care provider.141 Patients try an average of three OTC prod-
ucts before seeking help141; however, only half feel satisfied.7,141
Primary care providers should refer patients who are laxative 
refractory or intolerant to treatment to a gastroenterology pro-
vider for further assessment.28,140 Primary care providers may try 
a promotility agent or prosecretory agent while awaiting gastroen-
terology evaluation. Gastroenterology providers may further titrate 
promotility agents or prosecretory agents and/or consider further 
testing— such as anorectal manometry, barium or magnetic reso-
nance defecography, or colon transit time assessment— to identify 
F I G U R E  4   Management algorithm for the treatment of constipation. This figure has been modified from Sharma Handb Exp Pharmacol. 
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the underlying pathophysiology and guide treatment in treatment- 
refractory patients.11,28,50 While there is a lack of evidence in the 
literature to guide a symptom- based therapeutics approach, there 
is some evidence that different therapies may improve certain un-
derlying mechanisms. For example, biofeedback therapy— a be-
havioural training technique using visual feedback to correct pelvic 
floor contractions— is safe, effective and recommended for patients 
with defecation disorders on the basis of anorectal manometry and 
defecography findings,11,29,32,50,140 linaclotide and prucalopride ac-
celerate colonic transit time, and linaclotide and plecanatide improve 
abdominal pain (and the former has been shown recently to modify 
afferent gut and brain interactions).19 Likewise, rectal sensory re-
training may be helpful in addition to biofeedback therapy to address 
both rectal hyper- and hyposensitivity.
A gastroenterology provider may recommend alternative treat-
ments if other treatment options have failed.50 Acetylcholinesterase 
inhibitors, such as neostigmine, can dramatically increase GI mo-
tility and may be considered in hospitalised patients with colonic 
pseudo- obstruction; however, its use requires close observation 
and cardiorespiratory monitoring in the intensive care setting.50,142 
Furthermore, pyridostigmine, an oral acetylcholinesterase inhibi-
tor, may be considered in severe constipation, especially with co- 
existing autonomic dysfunction in patients who have previously 
responded to neostigmine or diabetes.143,144 Oral ingestion of 
a vibrating capsule alters colonic circadian rhythm and may im-
prove constipation by inducing more complete spontaneous bowel 
movements.145 Habit training (bowel or pelvic floor retraining) and 
psychological interventions (cognitive behavioural therapy, hypno-
therapy, psychological therapy) are also recommended for patients 
failing to respond to standard care.50,146 Total abdominal colec-
tomy is reserved for rare, severe cases of colonic inertia after all 
non- surgical options have failed and specialised testing such as co-
lonic manometry suggests underlying colonic neuropathy.11,32,50,147 
Continuous direct nerve stimulation (sacral nerve stimulation) is the 
least- invasive surgical option available, with fewer complications 
than other surgeries; however, data demonstrating efficacy are lack-
ing.50,147 Subcutaneous electrodes can stimulate the sacral nerve to 
induce propagating contractions and increase stool frequency.32,147 
Antegrade continence enema, an endosurgical procedure where ap-
pendicocecostomy or caecostomy is created to serve as a conduit 
to directly administer enemas into the caecum, has been described 
as an efficacious option to treat faecal incontinence and refractory 
constipation.148 The majority of cases and much of the literature are 
focused on the treatment of children; however, single- centre expe-
riences have described their long- term outcomes in adults.149- 161 A 
meta- analysis of observational studies, only three of which were 
prospective, suggested that approximately two thirds of antegrade 
continence enema procedures for constipation were efficacious, 
defined by continued use on follow- up or successful resolution of 
symptoms, and approximately 45% of antegrade continence enema 
procedures were associated with morbidity, most commonly wound 
infection and stomal stenosis, with a re- operation rate of >25%.162 
Given the low quality of evidence without randomised controlled 
trials and associated morbidity, antegrade continence enema cannot 
be recommended for treatment of severe constipation.
6.5 | Patient perspective
6.5.1 | Tools for assessing symptom severity
Patient QoL decreases with severity and duration of constipation 
and associated symptoms.7 Furthermore, patients with chronic 
constipation exhibit significant psychological stress and impaired 
health- related QoL compared to control subjects.163 Symptoms re-
ported as most bothersome are often also the most severely per-
ceived.7 Therefore, treatments focused on these symptoms are 
important to improve QoL.7 Improvement in constipation with both 
secretagogues73,75- 77,79 and biofeedback therapy138 can improve 
QoL.
In the absence of objective biomarkers for assessing con-
stipation severity, prospective stool diaries and validated se-
verity scales help assess patient- reported outcomes in clinical 
trials and manage patients clinically.164 The most commonly used 
scales include the Constipation Assessment Scale, Constipation 
Scoring System, Symptom Severity Score and Patient Assessment 
Constipation- Symptom (Table 3). These scales assess the presence 
of constipation, constipation severity and the most bothersome 
constipation- associated symptoms. Thorough review of stool dia-
ries and responses to severity scales may offer clinicians an oppor-
tunity to assess treatment efficacy from the patient's perspective. 
However, if physical stool diaries and scales are not completed in 
real time, they may be limited by their dependence on patient recall 
of bowel habits and symptoms.
New tools are becoming available to support the monitoring of 
patients with constipation, such as electronic health records, smart-
phone apps and electronic stool diaries. The National Institutes 
of Health Patient- Reported Outcomes Measurement Information 
System is increasingly incorporated into electronic health records 
as a measure of recording patient- reported outcomes.164 Within the 
GI domains of the National Institutes of Health Patient Reported 
Outcomes Measurement Information System, abdominal pain and 
constipation, as well as diarrhoea as a potentially treatment- related 
adverse event, are relevant to patients with constipation.164
With smartphone apps and diaries, gastroenterology provid-
ers can potentially review patients' symptoms as recorded in real 
time. The GI Patient Reported Outcomes Measurement Information 
System scales can be accessed via the MyGiHealth app online and on 
smartphones, which compare a patient's symptoms scores with those 
of the general population in the United States and generates a heat 
map of symptoms.164 This app can also track changes across time, al-
lowing gastroenterology providers to assess treatment efficacy and 
facilitate improved outcomes for both providers and patients.164 The 
Constipation Stool Diary is an app- based questionnaire used to track 
patient symptoms and medication use.25 Apps have demonstrated a 
level of accuracy comparable to a physical diary and may be patient 
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preferred.165 For example, apps may assist in tracking diet and the 
symptoms of IBS- C to see if there is a correlation.166 Administering 
scales via an app either in the clinic or in the advance of an appoint-
ment may also optimise resource use.
6.6 | Summary
CIC and IBS- C are historically classified as idiopathic; however, 
pathophysiological dysfunctions can be commonly identified in 
these constipation disorders, which could aid effective manage-
ment. In addition, pelvic floor disorders such as dyssynergic def-
ecation are common and often may present with overlapping 
symptoms of infrequent defecation and difficulty with defecation. 
Gastroenterology providers should be familiar with the constipa-
tion subtypes and their underlying pathophysiology, as well as key 
signalling pathways that may contribute to constipation. Although 
lifestyle and diet modifications are useful, laxatives remain the 
first- line treatment of constipation. For laxative- refractory cases, 
several classes of prokinetic and prosecretory agents are available. 
Familiarisation with the varied mechanisms of action, expected ef-
ficacy and side effects helps to select the appropriate treatment 
and meet patient expectations. Treatment algorithms are available 
to guide decision- making. Smartphone apps can help gastroen-
terology providers and patients track constipation symptoms and 
treatment response.
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TA B L E  3   Commonly used scales for assessing the severity of constipation




• Abdominal distension or bloating
• Change in gas passed rectally
• Reduced frequency of bowel 
movements
• Oozing liquid stool
• Rectal fullness or pressure
• Rectal pain with bowel movement
• Small stool volume
• Inability to defecate
Each item rated on a 3- point scale:
• 0 = no problem
• 1 = some problem
• 2 = severe problem
Total score range: 0- 16
• 0 = no constipation
•  16 = severe 





• Frequency of bowel movements
• Difficult or painful evacuation
• Completeness of evacuation
• Abdominal pain
• Time per attempt
• Type of assistance (none, laxatives, 
digital/enema)
• Number of unsuccessful attempts at 
evacuation in a 24- h period
• Duration of constipation
Each item rated on a five- point 
scale:
• 0 = none of the time
•  4 = all the timeOne item is 
rated from 0 to 2
Total score range: 0- 30
• 0 = normal
•  30 = severe 
constipationScore ≥15 
indicates constipation
Patient Assessment of 
Constipation- Symptoms170
Evaluates 12 items with three subscales:
• Abdominal (four items)
• Rectal (three items)
• Stool (five items)
Each item rated on a 5- point scale:
• 0 = symptom absent
• 1 = mild
• 2 = moderate
• 3 = severe
• 4 = very severe
Total score range: 0- 4
• Generated by dividing the 
total score by the number of 
questions completed
• Higher scores associated 
with higher symptom burden
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